Summary & Overview
HCPCS M1434: Patient on Oral Chemotherapy Near Encounter
HCPCS Level II code M1434 documents that a patient is on oral chemotherapy on or within 30 days after a denominator-eligible encounter. Nationally, capture of oral chemotherapy status matters for quality measurement, care coordination, and monitoring safe delivery of cancer therapy outside of infusion settings. The code signals active management of systemic anticancer treatment in outpatient settings and supports reporting for performance measures and care continuity.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what M1434 represents, typical sites of service, and the clinical context for use. The publication summarizes benchmarking and coding considerations, highlights implications for outpatient oncology workflows, and notes where input data is not available. It also outlines what to expect when integrating this code into quality reports and administrative claims workflows at a national level.
Billing Code Overview
HCPCS Level II code M1434 indicates a patient is on oral chemotherapy on or within 30 days after a denominator-eligible encounter. This code captures medication status related to systemic oral anticancer therapy and is used to identify patients receiving oral chemotherapy around a qualifying clinical visit.
-
Service type: Medication status / therapeutic management related to oral chemotherapy
-
Typical site of service: Ambulatory clinic or outpatient oncology setting, including physician offices and infusion or oncology clinics where oral chemotherapy is managed
Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with metastatic colorectal cancer presents for a follow-up oncology clinic visit within 30 days after a prior eligible encounter. The patient has been prescribed an oral chemotherapy agent (for example, capecitabine) taken at home. During the clinic visit the oncology nurse documents medication reconciliation, symptoms and toxicities, performance status, lab review (CBC, CMP) results obtained the same day or previously, and confirms adherence and planned dosing for the oral chemotherapy. The clinic encounter includes evaluation of treatment response, management of side effects, and coordination of supportive care and prescriptions. Billing for M1434 is applied to indicate the patient is on oral chemotherapy on or within 30 days after the denominator-eligible encounter, supporting quality measurement and payment processes.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a distinct E/M visit is provided in addition to other services during the encounter documenting oral chemotherapy management. |
59 |